SCHEMBL7908261

SCHEMBL7908261

CC(C)(C)OC(=O)NNc1ccc(N)cn1

nearest known ligand 0.45

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
GAA P10253 3/20 0.45
POLB P06746 2/20 0.45
MEN1 O00255 1/20 0.45
NPC1 O15118 1/20 0.45
RAB9A P51151 1/20 0.45
KMT2A Q03164 1/20 0.45
PTGS1 P23219 3/20 0.42
MAPKAPK2 P49137 3/20 0.38
APLNR P35414 1/20 0.37
HDAC1 Q13547 1/20 0.36
GSK3B P49841 1/20 0.36
DYRK1A Q13627 1/20 0.36
MAP4K4 O95819 1/20 0.35
MIF P14174 1/20 0.35
LMNA P02545 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31165993 1.00 GAA (0.45) GAAPOLBMEN1NPC1RAB9A
SCHEMBL56219 0.85 PTGS1 (0.50) RAB9APTGS1MAPKAPK2HDAC1GSK3B
SCHEMBL25752898 0.84 RAB9A (0.50) GAAPOLBMEN1NPC1RAB9A
SCHEMBL24660418 0.83 NNMT (0.55) GAAPOLBMEN1NPC1RAB9A
SCHEMBL15758463 0.82 RAB9A (0.46) GAAPOLBMEN1NPC1RAB9A
SCHEMBL27938545 0.82 GAA (0.45) GAAPOLBMEN1NPC1RAB9A
SCHEMBL2058148 0.81 HCAR3 (0.54) GAAPOLBMEN1NPC1RAB9A
SCHEMBL24660362 0.80 MAPK1 (0.49) GAAPOLBMEN1NPC1RAB9A
SCHEMBL15600409 0.80 GAA (0.70) GAAPOLBMEN1NPC1RAB9A
SCHEMBL27838436 0.80 GAA (0.46) GAAPOLBMEN1NPC1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-114437062-B Compound capable of being used as sodium channel regulator and application thereof 成都海博为药业有限公司 2024-05-17 CN disclosed
CN-114437062-A Compound capable of being used as sodium channel regulator and application thereof 成都海博为药业有限公司 2022-05-06 CN disclosed
CN-102227218-B Tnik inhibitor and use thereof CARNA BIOSCIENCES INC 2014-04-02 CN disclosed
CN-103153063-A Quinoline derivatives and MELK inhibitors containing the same ONCOTHERAPY SCIENCE INC 2013-06-12 CN disclosed
CN-102227218-A Tnik inhibitor and use thereof TESSHI YAMADA 2011-10-26 CN disclosed
US-6217845-B1 IMAGING; THERAPY ANORMED, INC. (CA) 2001-04-17 US disclosed
EP-0667859-B1 MOLECULE LABELLING USING 2-HYDRANINOPYRIDINE DERIVATIVES ANORMED INC (CA) 2000-08-23 EP disclosed
US-5753520-A BIOCHEMICAL CONJUGATED WITH A HYDRAZINE OR A HYDRAZONE COMPOUND AS DRUG DELIVERY; HIGH BIOLOGICAL SPECIFICITY; MEDICINE FOR IMAGING, THERAPY, RADIOACTIVE TAGGING JOHNSON MATTHEY INC. (US) 1998-05-19 US disclosed
US-5679778-A FOR FORMING CONJUGATES WITH MACROMOLECULES JOHNSON MATTHEY PUBLIC LIMITED COMPANY (GB) 1997-10-21 US disclosed
EP-0384769-B1 Protein labelling JOHNSON MATTHEY PLC (GB) 1996-04-24 EP disclosed
US-5420285-A Imaging for medicine JOHNSON MATTHEY, INC. (US) 1995-05-30 US disclosed
US-5371086-A Circulatory disorders side effect reduction THE GREEN CROSS CORPORATION (JP) 1994-12-06 US disclosed
WO-1994010149-A1 MOLECULE LABELLING USING 2-HYDRANINOPYRIDINE DERIVATIVES JOHNSON MATTHEY PUBLIC LIMITED COMPANY (GB) 1994-05-11 WO disclosed
US-5262415-A FOR TREATING DISEASES OF THE CIRCULATORY SYSTEM THE GREEN CROSS CORPORATION (JP) 1993-11-16 US disclosed
EP-0503627-A1 Aminopyridine compounds THE GREEN CROSS CORPORATION (JP) 1992-09-16 EP disclosed
EP-0384769-A2 Protein labelling JOHNSON MATTHEY PUBLIC LIMITED COMPANY (GB) 1990-08-29 EP disclosed